» Articles » PMID: 24767708

Ovarian Cancer

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2014 Apr 29
PMID 24767708
Citations 947
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.

Citing Articles

Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis.

Liu S, Lin H, Zhang K, Zhou Q, Shen Y J Ovarian Res. 2025; 18(1):32.

PMID: 39972314 PMC: 11837690. DOI: 10.1186/s13048-025-01620-7.


Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma.

Sato S, Shintani D, Kaneda Y, Nakamura R, Katoh T, Yano M Int J Clin Oncol. 2025; .

PMID: 39937426 DOI: 10.1007/s10147-024-02658-1.


Engineered CAF-cancer cell hybrid membrane biomimetic dual-targeted integrated platform for multi-dimensional treatment of ovarian cancer.

Yao Y, Zhang J, Huang K, Peng Y, Cheng S, Liu S J Nanobiotechnology. 2025; 23(1):83.

PMID: 39910555 PMC: 11796236. DOI: 10.1186/s12951-025-03165-9.


Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice.

Wang Y, Zhang C, Zeng H, Wang L, Wang Z, Han Z Cancer Immunol Immunother. 2025; 74(3):103.

PMID: 39904884 PMC: 11794933. DOI: 10.1007/s00262-025-03951-2.


Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review.

Silverwood S, Backer G, Galloway A, Reid K, Jeter A, Harrison M BMJ Oncol. 2025; 3(1):e000404.

PMID: 39886168 PMC: 11261692. DOI: 10.1136/bmjonc-2024-000404.